Press releases
- Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
- Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Spyre Therapeutics Announces Grants of Inducement Awards
- Spyre Therapeutics Announces $180 Million Private Placement
More ▼
Key statistics
On Friday, Spyre Therapeutics Inc (3920:BER) closed at 32.45, -24.36% below its 52-week high of 42.90, set on Mar 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 31.45 |
---|---|
High | 32.45 |
Low | 31.35 |
Bid | 31.35 |
Offer | 33.00 |
Previous close | 31.25 |
Average volume | 0.00 |
---|---|
Shares outstanding | 50.78m |
Free float | 35.73m |
P/E (TTM) | -- |
Market cap | 1.77bn USD |
EPS (TTM) | -71.35 USD |
Data delayed at least 15 minutes, as of May 31 2024 19:08 BST.
More ▼